Patents Assigned to ACADEMY OF MILITARY MEDICAL SCIENCES
-
Patent number: 8846884Abstract: The present invention provides a method for enrichment and isolation of endogenous transcription factors and their complexes. Also, this invention provides corresponding tandem arrays of concatenated transcription factor response elements (catTFRE). The method employs the property of transcription factors binding to sequence-specific DNA elements during regulation of gene expression. The catTFREs are designed and synthesized as concatenate dual copies of DNA response elements for various transcription factors. The DNA sequence of synthesized catTFRE is cloned to a target vector. Biotinylated catTFRE with 200 bp arms is prepared by PCR strategy. For enrichment and isolation of endogenous transcription factors and their complexes, the biotinylated catTFRE is immobilized to streptavidin-coated magnetic beads and then incubated with nuclear extract. Thereby endogenous transcription factors and their complexes are isolated from nuclear extract.Type: GrantFiled: December 28, 2012Date of Patent: September 30, 2014Assignees: Baylor College of Medicine, Institute of Radiation Medicine, China Academy of Military Medical SciencesInventors: Jun Qin, Chen Ding, Qiongming Liu, Mingwei Liu, Wanlin Liu, Lei Song
-
Patent number: 8829001Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: GrantFiled: September 28, 2009Date of Patent: September 9, 2014Assignee: The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. ChinaInventors: Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Patent number: 8802669Abstract: Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B.Type: GrantFiled: May 27, 2010Date of Patent: August 12, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A. ChinaInventors: Song Li, Xiaoqian Xu, Guoming Zhao, Lili Wang, Hua Guan, Junhai Xiao, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xiaokui Wang, Xinbo Zhou, Hongying Liu
-
Patent number: 8765925Abstract: A method for preparation of Timosaponin BII, which uses Chinese traditional medicine Rhizoma Anemarrhenae or fresh rhizoma or fibrous root of Anemarrhena asphodeloides Bge. as raw material, and comprises isolation of Timosaponin BII by one or more processes selected from solvent extraction, resin adsorption, polyamide chromatography, reversed phase column chromatography, Sephadex LH-20 column chromatography, etc, combining with conventional drying method such as reduced pressure drying, freeze drying, spray drying, and so on. Timosaponin BII obtained by the present method is of over 90% purity, and the method is simple, practicable and suitable for industrial production.Type: GrantFiled: April 21, 2005Date of Patent: July 1, 2014Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Baiping Ma, Hao Chen, Chengqi Xiong, Liping Kang, Jie Zhang
-
Patent number: 8759355Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor ? (hPPAR?)-associated diseases and risk factors.Type: GrantFiled: July 18, 2008Date of Patent: June 24, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A.Inventors: Song Li, Yanbo Yang, Junhai Xiao, Wu Zhong, Zhibing Zheng, Xingzhou Li, Yunde Xie, Lili Wang, Hongying Liu
-
Publication number: 20140080840Abstract: Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound.Type: ApplicationFiled: December 6, 2011Publication date: March 20, 2014Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
-
Patent number: 8674136Abstract: Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection, is provided.Type: GrantFiled: May 16, 2011Date of Patent: March 18, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Ping Liu, Junhai Xiao, Zhibing Zheng, Yunde Xie, Guoming Zhao, Xiaokui Wang, Lili Wang, Xingzhou Li, Xinbo Zhou
-
Publication number: 20140057804Abstract: The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.Type: ApplicationFiled: March 14, 2012Publication date: February 27, 2014Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lili Wang, Shengqian Yang, Long Long, Junhai Xiao, Song Li
-
Publication number: 20130344101Abstract: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD.Type: ApplicationFiled: September 20, 2011Publication date: December 26, 2013Applicant: AFFILIATED HOSPITAL OF ACADEMY OF MILITARY MEDICAL SCIENCES, PLAInventors: Yongzhi Xi, Yuan Luo
-
Publication number: 20130331604Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.Type: ApplicationFiled: August 16, 2013Publication date: December 12, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Ll, Guoming Zhao, Xiaokui Wang, Hongying Liu
-
Publication number: 20130310310Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.Type: ApplicationFiled: August 11, 2011Publication date: November 21, 2013Applicants: Chengdu Yiping Medical Science & Technology Co., Ltd., Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Keliang Liu, Yuanjun Liang, Xiaoyu Xu, Sicheng Li
-
Publication number: 20130231369Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.Type: ApplicationFiled: April 8, 2011Publication date: September 5, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Yunfeng Li, Rifang Yang, Youzhi Zhang, Yongzhen Li, Zengliang Jin, Peng Li, Li Yuan, Liuhong Yun, Nan Zhao, Cheng Zhang, Xiaodan Xu, Rusheng Zhao, Hongxia Chen, Rui Xue, Juanjuan Qin, Zhenzhen Wang, Jiazhi Yao
-
Publication number: 20130225423Abstract: The present invention provides a method for enrichment and isolation of endogenous transcription factors and their complexes. Also, this invention provides corresponding tandem arrays of concatenated transcription factor response elements (catTFRE). The method employs the property of transcription factors binding to sequence-specific DNA elements during regulation of gene expression. The catTFREs are designed and synthesized as concatenate dual copies of DNA response elements for various transcription factors. The DNA sequence of synthesized catTFRE is cloned to a target vector. Biotinylated catTFRE with 200 bp arms is prepared by PCR strategy. For enrichment and isolation of endogenous transcription factors and their complexes, the biotinylated catTFRE is immobilized to streptavidin-coated magnetic beads and then incubated with nuclear extract. Thereby endogenous transcription factors and their complexes are isolated from nuclear extract.Type: ApplicationFiled: December 28, 2012Publication date: August 29, 2013Applicants: Baylor College of Medicine, Institute of Radiation Medicine, China Academy of Military Medical SciencesInventors: Institute of Radiation Medicine, China Academy of Military Medical Sciences, Baylor College of Medicine
-
Publication number: 20130210750Abstract: The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in Sequence 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin.Type: ApplicationFiled: September 9, 2011Publication date: August 15, 2013Applicant: Institute of Microbiology and Epidemiology Academy of Military Medical SciencesInventors: Hui Wang, Tao Li, Qin Wang, Wei Tu, Xiaojun Hou
-
Publication number: 20130203754Abstract: Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification.Type: ApplicationFiled: June 9, 2011Publication date: August 8, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Rifang Yang, Yunfeng Li, Yongzhen Li, Nan Zhao, Liuhong Yun, Juanjuan Qin, Zhongyao Feng, Youzhi Zhang
-
Publication number: 20130190319Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.Type: ApplicationFiled: August 2, 2011Publication date: July 25, 2013Applicant: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCESInventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
-
Publication number: 20130157380Abstract: A multiassay immunochromatographic chip comprises: a viscous bottom lining (1), a sample pad (2), a bonding pad (3), an analysis membrane (4) and a water absorption pad (5). The bonding pad (3) fixedly has a plurality of assay binding substances (6) and a control binding substance (7), the assay binding substance (6) is formed by joining a tracer (8) and a liquid-phase detection probe (9), the control binding substance (7) is formed by joining the tracer (8) and a liquid-phase control probe (11); the analysis membrane (4) is provided with a detection matrix unit (12), each detection matrix unit comprises a detection zone (13) and a control zone (14), wherein the detection zone (13) consists of a plurality of solid phase detection probes (15) and the control zone (14) consists of a solid phase control probe (16). Organic integration of immunochromatographic reaction modes and chip assay matrix settings enables high throughput assay of multiple target substances with one sample load.Type: ApplicationFiled: August 18, 2011Publication date: June 20, 2013Applicant: INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PLAInventors: Lei Zhou, Zhaobiao Guo, Ruifu Yang
-
Publication number: 20130116256Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 16, 2011Publication date: May 9, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Lili Wang, Kunlun He, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Xin Li, Guoliang Hu
-
Publication number: 20130085183Abstract: Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection, is provided.Type: ApplicationFiled: May 16, 2011Publication date: April 4, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Ping Liu, Junhai Xiao, Zhibing Zheng, Yunde Xie, Guoming Zhao, Xiaokui Wang, Lili Wang, Xingzhou Li, Xinbo Zhou
-
Patent number: 8410105Abstract: The present invention relates to substituted pyridazinylamine derivatives of the formula I or pharmaceutically acceptable salts or hydrates thereof, wherein the substituents are defined as in the description, their preparation process, pharmaceutical compositions comprising them, and uses of the said compounds as picorna virus inhibitors for prevention and/or treatment of diseases caused by picorna viruses.Type: GrantFiled: November 15, 2010Date of Patent: April 2, 2013Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Chunlai Mi, Zhibing Zheng, Guoming Zhao, Xinbo Zhou, Zehui Gong